IBRX - ImmunityBio, Inc.

QQQ $ 614.02 $ -7.77 (-1.25 %)

DIA $ 469.10 $ -2.95 (-0.62 %)

SPY $ 671.32 $ -5.15 (-0.76 %)

TLT $ 89.69 $ 0.13 (0.15 %)

GLD $ 366.51 $ -0.60 (-0.16 %)

Previous Close

$ 2.15

Open

$ 2.14

Bid

$ 2.15 x 7,859

Ask

$ 2.16 x 4,250

Day's Range

$ 2.12 - $ 2.21

52 Week Range

$ 1.83 - $ 5.88

Volume

13,359,911

Average Volume

Market Cap

2.12B

Beta (5Y Monthly)

$ 1.47

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	08-05-2025	06-30-2025	10-Q
3	05-12-2025	03-31-2025	10-Q
4	03-03-2025	01-01-1970	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-12-2024	06-30-2024	10-Q
7	05-09-2024	03-31-2024	10-Q
8	03-19-2024	12-31-2023	10-K
9	11-09-2023	09-30-2023	10-Q
10	08-08-2023	06-30-2023	10-Q
11	05-11-2023	03-31-2023	10-Q
12	03-01-2023	12-31-2022	10-K
13	11-09-2022	09-30-2022	10-Q
14	08-08-2022	06-30-2022	10-Q
15	05-10-2022	03-31-2022	10-Q
16	03-01-2022	12-31-2021	10-K
17	11-12-2021	09-30-2021	10-Q
18	08-12-2021	06-30-2021	10-Q
19	05-14-2021	03-31-2021	10-Q
20	03-04-2021	12-31-2020	10-K
21	11-09-2020	09-30-2020	10-Q
22	08-07-2020	06-30-2020	10-Q
23	05-11-2020	03-31-2020	10-Q
24	03-25-2020	12-31-2019	10-K
25	11-05-2019	09-30-2019	10-Q
26	08-06-2019	06-30-2019	10-Q
27	05-08-2019	03-31-2019	10-Q
28	03-13-2019	12-31-2018	10-K
29	11-07-2018	09-30-2018	10-Q
30	08-06-2018	06-30-2018	10-Q
31	05-07-2018	03-31-2018	10-Q
32	03-12-2018	12-31-2017	10-K
33	11-07-2017	09-30-2017	10-Q
34	08-07-2017	06-30-2017	10-Q
35	05-08-2017	03-31-2017	10-Q
36	03-15-2017	12-31-2016	10-K
37	11-10-2016	09-30-2016	10-Q
38	08-15-2016	06-30-2016	10-Q
39	05-16-2016	03-31-2016	10-Q
40	03-30-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

D. Boral Capital Maintains Buy on Immunity...
11/05/2025 14:00:37

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

ImmunityBio Q3 EPS $(0.07) Beats $(0.10) E...
11/05/2025 06:48:15

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) b...

HC Wainwright & Co. Reiterates Buy on Immu...
09/10/2025 10:57:59

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $8 price t...

D. Boral Capital Maintains Buy on Immunity...
09/08/2025 14:11:25

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

ImmunityBio Announces Paradigm Changing Fi...
09/08/2025 12:35:37

Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lo...

whats-going-on-with-immunitybio-shares-tuesday

What's Going On With ImmunityBio Shares Tu...
08/26/2025 16:33:41

ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease...

D. Boral Capital Maintains Buy on Immunity...
08/26/2025 16:26:10

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

ImmunityBio's Chemotherapy-Free Combo Show...
08/26/2025 12:34:48

First chemotherapy-free trial combining ANKTIVA, an IL-15 agonist, natural killer (NK) cell therapy, and Optune immune-stimulat...

D. Boral Capital Maintains Buy on Immunity...
08/19/2025 14:47:18

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

ImmunityBio Opens New Phase 2 Study To Ass...
08/19/2025 12:34:59

D. Boral Capital Maintains Buy on Immunity...
08/14/2025 12:35:13

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

ImmunityBio Announces Early QUILT-106 Phas...
08/13/2025 12:36:19

Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of ...

ImmunityBio's ANKTIVA Now Available At Hou...
08/11/2025 12:33:56

ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affai...

D. Boral Capital Maintains Buy on Immunity...
08/05/2025 12:09:23

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.

ImmunityBio Q2 EPS $(0.10) Beats $(0.11) E...
08/05/2025 11:41:08

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) b...

D. Boral Capital Maintains Buy on Immunity...
07/25/2025 11:47:23

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.

ImmunityBio Reports 60% Q2 Revenue Growth ...
07/25/2025 10:10:23

ImmunityBio Announced Registered Direct Of...
07/25/2025 10:05:15

la-times-going-public-patrick-soon-shiong-plans-green-bay-style-ownership-to-democratize-143-year-old-paper

LA Times Going Public? Patrick Soon-Shiong...
07/22/2025 06:36:48

Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.

D. Boral Capital Maintains Buy on Immunity...
07/08/2025 11:19:21

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $30 price target.